The purpose of this stud yis to estimate the effectiveness of AR-623 inducing a complete remission in first relapse acute promyocytic leukemia (APL) patients who have not received oral all-trans-retinoic acid (ATRA) within one year.
Showing the most recent 10 out of 565 publications